| Literature DB >> 26640738 |
Carsten Buhmann1, Eik Vettorazzi2, Christian Oehlwein3, Fred Rikkers1, Monika Poetter-Nerger1, Alessandro Gulberti4, Christian Gerloff1, Christian K Moll4, Wolfgang Hamel5.
Abstract
Objective. To determine the influence of deep brain stimulation (DBS) on daily routine driving behavior in Parkinson's disease (PD) patients. Methods. A cross-sectional questionnaire survey was done in 121 DBS-PD patients. The influences of patient characteristics and DBS on current driving and driving at time of surgery and the predictive value of the preoperative levodopa-test on postoperative driving were evaluated. Results. 50% of 110 driving-license holders currently drove. 63.0% rated themselves as safe drivers, 39.4% reported improvement, and 10.9% noted deterioration in driving after DBS surgery. Inactive drivers had quit driving mainly due to disease burden (90.9%). Active drivers were younger, more often males, and less impaired according to H&Y and MMSE, had surgery more recently, and reported more often overall benefit from DBS. H&Y "on" and UPDRS III "off" scores at time of surgery were lower in pre- and postoperative active than in inactive drivers. Tremor and akinesia were less frequent reasons to quit driving after than before DBS surgery. Postoperatively, 22.7% (10/44) of patients restarted and 10.6% (7/66) of patients discontinued driving, independently of H&Y stage. The preoperative levodopa-test was not predictive for the postoperative driving outcome. Conclusion. 50% of PD patients with DBS drive. DBS surgery changes daily routine driving behavior.Entities:
Year: 2015 PMID: 26640738 PMCID: PMC4657404 DOI: 10.1155/2015/608961
Source DB: PubMed Journal: Parkinsons Dis ISSN: 2042-0080
The table shows patient characteristics of drivers at time of survey. Data are shown as means with standard deviation [SD]. Significant different frequencies between active and inactive drivers are labeled with an asterix (∗). “H&Y”: Hoehn and Yahr; “QoL”: quality of life.
| Time of survey | ||||
|
| ||||
| All | Active drivers | Inactive drivers |
| |
|
| ||||
| Age | 65.2 [9.4] | 63.3 [8.8] | 67.0 [9.7] | 0.04 |
| Gender (male) (%) | 68.2 | 78.2 | 58.2 | 0.02 |
| H&Y stage | 3.0 [0.9] | 2.6 [0.7] | 3.5 [1.0] | <0.001 |
| MMSE (total points) | 27.0 [2.9] | 28.0 [1.7] ( | 26.0 [3.3] | <0.001 |
| MMSE category (%) | ||||
| Normal (>26) | 71.6 | 83.3 | 60.0 | 0.008 |
| Borderline (24–26) | 20.2 | 14.8 | 25.5 | |
| Dementia likely (<24) | 8.3 | 1.9 | 14.5 | |
| Disease duration (years) | 16 [6.5] | 14.9 [6.4] | 17.1 [6.4] | 0.08 |
| Driving experience (years) | 39.1 [13.3] | 41.0 [12.0] | 37.0 [14.4] | 0.12 |
| Duration of DBS (years) | 4.1 [3.2] | 3.5 [2.7] | 4.7 [3.6] | 0.05 |
| Dependency on a car (%) | 46.3 | 70.9 | 20.8 | <0.001 |
| QoL reduced without driving (%) | 61.1 | 81.8 | 39.6 | <0.001 |
| Could rely on another driver (%) | 82.7 | 83.6 | 81.8 | 0.80 |
| Total benefit from DBS (%) | 92.7 | 98.2 | 87.3 | 0.02 |
| Would do DBS again (%) | 90.0 | 98.2 | 81.8 | 0.002 |
Figure 1Parkinson's disease-related symptoms responsible for quitting driving. Symptoms related to Parkinson's disease and mentioned by the patients to be responsible alone or in combination for cessation of driving before or after DBS surgery are shown as occurrence in percentage (%). Significant different frequencies are labeled with an asterix (∗).
The table shows patient characteristics of all drivers and compares patient characteristics of active and inactive drivers at time of DBS surgery (within 3 months before and 12 months after surgery). Furthermore, a comparison of patients who did or did not restart driving is given. Data are shown as means with standard deviation [SD]. Significant different frequencies between active and inactive drivers are labeled with an asterix (∗).
| Time of DBS surgery | |||||
|
| |||||
| Within 3 months |
| All (110) | Active drivers ( | Inactive drivers ( |
|
|
| |||||
| Age (years) | 110 | 61.1 [9.1] | 61.2 [8.2] | 60.9 [10.3] | 0.89 |
| Gender (male) (%) | 110 | 68.2 | 80.3 | 50.0 | <0.001 |
| H&Y stage (stage) | 102 | 2.8 [0.8] | 2.7 [0.8] | 3.0 [0.7] | 0.06 |
| Disease duration (years) | 110 | 11.9 [5.6] | 11.5 [5.4] | 12.7 [5.9] | 0.29 |
| MMSE (total points) | 109 | 28.5 [1.5] | 28.5 [1.6] ( | 28.5 [1.3] | 0.83 |
| MMSE category (%) | 109 | ||||
| Normal (>26) | 96 | 88.1 | 86.2 | 90.9 | 0.45 |
| Borderline (24–26) | 13 | 11.9 | 13.8 | 9.1 | |
| UPDRS III in “ON” (score) | 77 | 18.4 [7.3] | 18.0 [6.7] | 19.0 [8.1] | 0.58 |
| UPDRS III in “OFF” (score) | 75 | 37.7 [11.7] | 35.2 [10.3] | 41.7 [12.8] | 0.02 |
| Improvement in levodopa-test (%) | 75 | 51.8 [17.7] | 49.8 [18.0] | 54.7 [17.0] | 0.23 |
|
| |||||
| Within 12 months |
| All (110) | Active drivers ( | Inactive drivers ( |
|
|
| |||||
| Age (years) | 110 | 61.1 [9.1] | 60.5 [8.7] | 62.3 [9.6] | 0.31 |
| Gender (male) (%) | 110 | 67.9 | 77.9 | 51.2 | 0.004 |
| H&Y stage (stage) | 102 | 2.8 [0.8] | 2.6 [0.7] | 3.1 [0.8] | 0.003 |
| MMSE (total points) | 108 | 28.5 [1.5] | 28.6 [1.5] ( | 28.3 [1.5] ( | 0.37 |
| MMSE category (%) | 108 | ||||
| Normal (>26) | 95 | 88.0 | 91.0 | 82.9 | 0.22 |
| Borderline (24–26) | 13 | 12.0 | 9.0 | 17.1 | |
| Disease duration (years) | 110 | 11.9 [5.6] | 11.5 [5.8] | 12.8 [5.3] | 0.25 |
| UPDRS III in “ON” (score) | 77 | 18.4 [7.3] | 17.8 [6.8] | 19.2 [8.0] | 0.41 |
| UPDRS III in “OFF” (score) | 75 | 37.7 [11.7] | 34.7 [10.1] | 42.1 [12.7] | 0.006 |
| Improvement in levodopa-test (%) | 75 | 51.8 [17.7] | 49.4 [19.1] | 55.1 [15.4] | 0.18 |
|
| |||||
| Patients restart driving |
| All (110) | Yes [ | No [ |
|
|
| |||||
| Age (years) | 110 | 61.1 [9.1] | 56.6 [10.7] | 61.5 [8.8] | 0.11 |
| Gender (male) (%) | 110 | 68.2 | 70.0 | 68.0 | 0.90 |
| H&Y stage (stage) | 102 | 2.8 [0.8] | 2.7 [0.5] | 2.8 [0.8] | 0.57 |
| MMSE (total points) | 109 | 28.5 [1.5] | 28.9 [1.1] ( | 28.4 [1.5] ( | 0.36 |
| MMSE category (%) | 109 | ||||
| Normal (>26) | 96 | 88.1 | 100.0 | 86.9 | 0.10 |
| Borderline (24–26) | 13 | 11.9 | 0.0 | 13.1 | |
| Disease duration (years) | 110 | 11.9 [5.6] | 12.8 [8.0] | 11.9 [5.4] | 0.60 |
| UPDRS III in “ON” (score) | 77 | 18.4 [7.3] | 18.3 [7.7] | 18.4 [7.3] | 0.98 |
| UPDRS III in “OFF” (score) | 75 | 37.7 [11.7] | 40.7 [9.7] | 37.6 [11.9] | 0.54 |
| Improvement in levodopa-test (%) | 75 | 51.8 [17.7] | 52.5 [20.3] | 51.7 [17.6] | 0.91 |